

CIN No.: L15142DL1974PLC007349 405, Deepali Building, 92, Nehru Place

New Delhi - 110019, India

t: +91-41889999 f: +91-46597994

**Scrip Code**: 519003

e: corporate@modinaturals.com

www.modinaturals.com

08th February 2025

Corporate Relationship Department **BSE Limited** P. J. Towers, Dalal Street, Fort, Mumbai - 400 001

Dear Sir / Madam,

# <u>Sub: Integrated Filing (Financial) for the quarter and nine months ended</u> <u>December 31, 2024.</u>

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 dated January 02, 2025, please find enclosed Integrated Filing (Financials) for the quarter and nine months ended December 31, 2024.

The same is also available on the website of the Company i.e., www.modinaturals.com

Kindly take the above intimation on record.

Thanking you!

Yours Faithfully, for MODI NATURALS LIMITED

Akshay Modi Jt. Managing Director DIN: 03341142

Encl: as above

#### DOOGAR & ASSOCIATES

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REVIEW REPORT ON CONSOLIDATED UNAUDITED QUARTERLY AND YEAR TO DATE FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENED

## TO THE BOARD OF DIRECTORS OF MODI NATURALS LIMITED

- We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of MODI NATURALS LIMITED (the "Company" or "Parent") and its subsidiary (the Parent and its subsidiary together referred to as the "Group"), for the quarter and nine months ended 31<sup>st</sup> December 2024, attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
- 2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act,2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). A review of Interim financial information consists of making inquiries, primarily of Parent's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under Section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

- 4. The Statement includes the results of its one subsidiary company named Modi Biotech Private Limited (100% Holding)
- 5. Based on our review conducted and procedures stated in paragraph 3 above and based on be considerations of the review report of other auditor referred to in paragraph six below, nothing has come to our attention that causes us to believe that the accompanying Statement of Consolidated Unaudited Financial Results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



### **DOOGAR & ASSOCIATES**

CHARTERED ACCOUNTANTS

6. We did not review the financial results of its subsidiary company included in the consolidated unaudited financial results, whose financial results reflect total revenues of Rs. 8180.40 lacs; total net profit after tax of Rs 521.42 lacs and total comprehensive profit of Rs 521.92 Lacs for the quarter ended December 31, 2024, as considered in the Statement. These financial results have been reviewed by other auditor whose report has been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary, is based solely on the reports of the other auditor and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of this matter.

For Doogar & Associates

Chartered Accountants

FRN No.000561N2 & AS.

MUKESH GOYAL

Partner

M.No. 081810

UDIN: 25081810BMIAAV6707

Place: New Delhi Date: 28/01/2025

### MODI NATURALS LIMITED

Regd. Office: 405, Deepali Building, 92, Nehru Place, New Delhi-110019
Corporate Office: D-54, 2nd Floor, Okhla Industrial Area, Phase-I, New Delhi-110020
(CIN: L15142DL1974PLC007349), Tel: 011-41889999, E-mail: cs.mnl@modinaturals.org, Website: www.modinaturals.com, Statement of Consolidated Unaudited Financial Results for the Quarter and Nine Months ended 31-12-2024

PART	1:				(₹ Lakhs,	Unless Othe	rwise Stated)			
			Consolidated							
Particulars			Quarter Ende	d	Nine Mon	Year Ended				
	Particulars		30/09/2024	31/12/2023	31/12/2024	31/12/2023	31/03/2024			
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)			
1	Revenue from Operations	17901.68	14655.74	10446.55	47322.86	28002.36	39982.24			
II	Other Income	125.55	71.56	8.22	253.26	26.26	115.36			
111	Total Income (I+II)	18027.23	14727.30	10454.77	47576.12	28028.62	40097.60			
IV	Expenses									
	(a) Cost of materials consumed	15785.95	11315.18	7315.59	36006.50	18689.15	29625.74			
	(b) Purchases of stock-in-trade	171.72	181.30	80.74	470.27	428.71	642.60			
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-	(1823.59)	(575.88)	788.08	102.13	2063.01	(268.34)			
	(d) Employee benefits expense	780.48	829.53	668.30	2366.92	1855.39	2613.12			
	(e) Finance costs	361.92	311.45	202.09	987.40	434.17	773.81			
	(f) Depreciation and amortisation expense	201.11	203.37	172.24	600.13	249.25	421.36			
	(g) Other expenses	1657.77	1571.00	1719.26	4386.88	4616.52	6462.28			
	Total Expenses (IV)	17135.36	13835.95	10946.30	44920.23	28336.20	40270.57			
٧	Profit / (Loss) before exceptional items and tax (III-IV)	891.87	891.35	(491.53)	2655.89	(307.58)	(172.97)			
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00			
VII	Profit before tax (V-VI)	891.87	891.35	(491.53)	2655.89	(307.58)	(172.97)			
VIII	Tax Expense									
	(a) Current Tax	0.00	25.00	(30.00)	50.00	0.00	49.48			
	(b) Deferred Tax	109.96	108.13	(42.78)	319.40	(43.78)	(84.61)			
IX	Profit (Loss) for the period (VII - VIII)	781.91	758.22	(418.75)	2286.49	(263.80)	(137.84)			
X	Other Comprehensive Income					Filter				
A.	(i). Items that will not be reclassified to profit or loss	0.50	0.50	0.00	1.50	1.00	16.02			
-	(ii). Income tax relating to items that will not be reclassified to profit or loss									
В.	(i). Items that will be reclassified to profit or loss									
	(ii). Income tax relating to items that will be reclassified to profit or loss									
	Other comprehensive income for the period	0.50	0.50	0.00	1.50	1.00	16.02			
XI	Total Comprehensive Income for the period (IX +X)	782.41	758.72	(418.75)	2287.99	(262.80)	(121.82)			
XII	Paid up equity share capital (Face value Rs. 10/- per share)	1330.64	1330.64	1330.64	1330.64	1330.64	1330.64			
XIII	Other Equity excluding revaluation reserves						7731.13			
XIV	Earnings Per Share (EPS)	The Manual Manua								
- 1	a) Basic (Rs.)	5.88	5.70	(3.15)	17.19	(1.98)	(0.92)			
	b) Diluted (Rs.)	5.88	5.70	(3.15)	17.19	(1.98)	(0.92)			

#### NOTES :

Place: New Delhi

Date: 28/01/2025

- The above consolidated results were reviewed by the Audit Committee and were approved by the Board of Directors in their respective meetings held on 28th January, 2025. The Statutory Auditors have carried out the limited review of the above consolidated results for the quarter ended 31st December 2024.
- The above consolidated results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended, prescribed under Section 133 of the Companies Act 2013 and other recognised accounting practices and policies to the extent applicable.
- The Subsidiary Company Modi Biotech Private Limited (MBPL) has a net additional positive cash flow of Rs 879 lakhs from accumulated GST Input available as on 31st March, 2024, which has been released during the nine month ended 31st December, 2024 by virtue of set off against the sales. Out of above net additional cash flow, Rs. 322 lakhs related to quarter ended 30th June, 2024, Rs. 337 lakhs related to quarter ended 30th September, 2024 and Rs. 220 lakhs related to quarter ended 31st December, 2024.
- During the F.Y. 2023-24, post commencement of the Subsidiary Company's -MBPL Manufacturing operation at Raipur, one of the the Machinery components in the plant broken down which required repair and ultimate replacement. Owning to such breakdown, there was intermittent stoppage of plant and operation partially as well as fully. The company has lodged claimed to insurances company for machinery breakdown as well as for the loss of Profit. The insurance claim shall be accounted for in these accounts upto acceptance by the insurance company and finality of the matter.
- The previous periods' figures have been regrouped and reclassified wherever considered necessary to make them comparable with the current periods' figures.

For Modi Naturals Limited

ASSOC Firm Jegn. No. 170 000561N \* New Delhi



Managing Director
DIN: 00187078

## **DOOGAR & ASSOCIATES**

CHARTERED ACCOUNTANTS

INDEPENDENT AUDITOR'S REVIEW REPORT ON STANDALONE UNAUDITED QUARTERLY AND NINE MONTHS ENDED 31<sup>st</sup> DECEMBER, 2024 FINANCIAL RESULTS OF THE COMPANY PURSUANT TO THE REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENED

TO THE BOARD OF DIRECTORS OF MODI NATURALS LIMITED

- 1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of MODI NATURALS LIMITED (the "Company"), for the quarter and nine months ended 31<sup>st</sup> December 2024, attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('the regulation') as amended (the "Listing Regulations").
- 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("IndAS34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
- 4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the afore said Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Doogar & Associates

Chartered Accountants

FRN No.000561N & AS,

MUKESH GOYALOGACO

Partner

M.No. 081810

UDIN: 25081810BMIAAU4013

Place: New Delhi Date: 28/01/2025

# **MODI NATURALS LIMITED**

Regd. Office: 405, Deepali Building, 92, Nehru Place, New Delhi-110019 Corporate Office: D-54, 2nd Floor, Okhla Induatrial Area, Phase-I, New Delhi-110020

(CIN: L15142DL1974PLC007349), Tel: 011-41889999, E-mail: cs.mnl@modinaturals.org, Website: www.modinaturals.com,

Statement of Standalone Unaudited Financial Results for the Quarter and Nine Months ended 31-12-2024

PART	1:				(1	Lakhs, Unless O	therwise Stated)
		Standalone					
	Particulars	Quarter Ended		d	Ninemon	HEnded	Year Ended 31/03/2024
	Fatticulais		30/09/2024	31/12/2023	31/12/2024	31/12/2023	
-	(Refer Notes Below)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from Operations	9729.55	6619.71	9748.74	23338.69	27304.55	35776.61
11	Other Income	117.28	66.55	7.42	238.27	25.08	112.86
111	Total Income (I+II)	9846.83	6686.26	9756.16	23576.96	27329.63	35889.47
IV	Expenses						
	(a) Cost of materials consumed	8861.50	4106.17	6426.10	16090.52	17799.66	24996.07
	(b) Purchases of stock-in-trade	171.72	181.30	80.74	470.27	428.71	642.60
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(1734.62)	(121.40)	1120.02	(142.71)	2394.95	900.80
	(d) Employee benefits expense	615.87	669.11	576.83	1889.73	1763.92	2347.95
	(e) Finance costs	116.09	93.99	95.16	310.84	327.24	428.67
	(f) Depreciation and amortisation expense	41.49	43.99	35.53	124.47	106.59	150.25
	(g) Other expenses	1514.29	1441,13	1670.37	4010.08	4561.02	6328.11
	Total Expenses (IV)	9586.34	6414.29	10004.75	22753.20	27382.09	35794.45
٧	Profit / (Loss) before exceptional items and tax (III-IV)	260.49	271.97	(248.59)	823.76	(52.46)	95.02
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00
VII	Profit before tax (V-VI)	260.49	271.97	(248.59)	823.76	(52.46)	95.02
VIII	Tax Expense						
	(a) Current Tax	0.00	25.00	. (30.00)	50.00	0.00	49.50
-	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	(45.63)
IX	Profit' (Loss) for the period (VII - VIII)	260.49	246.97	(218.59)	773.76	(52.46)	91.15
X	Other Comprehensive Income						
A.	(i). Items that will not be reclassified to profit or loss	. 0.00	0.00	0.00	0.00	1.00	14.02
	(ii). Income tax relating to items that will not be reclassified to profit or loss						
B.	(i). Items that will be reclassified to profit or loss						
	(ii). Income tax relating to items that will be reclassified to profit or loss						
	Other comprehensive income for the period	0.00	0.00	0.00	0.00	1.00	14.02
ΧI	Total Comprehensive Income for the period (IX +X)	260.49	246.97	(218.59)	773.76	(51.46)	105.17
XII	Paid up equity share capital (Face value Rs. 10/- per share)	1330.64	1330.64	1330.64	1330.64	1330.64	1330.64
XIII	Other Equity excluding revaluation reserves						7971.96
XIV	Earnings Per Share (EPS)						
	a) Basic (Rs.)	1.96	1.86	(1.64)	5.81	(0.40)	0.82
	b) Diluted (Rs.)	1.96	1.86	(1.64)	5.81	(0.40)	0.82

#### NOTES :

- 1 The above standalone results were reviewed by the Audit Committee and were approved by the Board of Directors in their respective meetings held on 28th January, 2025. The Statutory Auditors have carried a limited review of the above standalone financial results for the quarter ended 31st Decemberber 2024
- The above standalone results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015, as amended, prescribed under Section 133 of the Companies Act 2013 and other recognised accounting practices and policies to the extent applicable.
- 3 In accordance with the Indian Accounting Standard -Ind AS 108 'Operating Segment, the Company has organised the business into two segments viz. Branded Business and Bulk Business. The Branded business includes consumer oil and food business. The Bulk business includes bulk oil business. Accordingly, the Company has reported its segmental results for these segments.

405, Deepall Bullo

The previous periods' figures have been regrouped and reclassified wherever considered necessary to make them comparable with the current periods' figures.

For Modi Naturals Limited

Managing Director

Place : New Delhi Date : 28/01/2025



#### MODI NATURALS LIMITED

#### STANDALONE SEGMENT INFORMATION FOR THE QUARTER ENDED 31st DECEMBER 2024

(Rs in Lacs)

Sr. No.	Particulars	Qtr Ended			Nine Months Ended		Year Ended
		Dec-24	Sep-24	Dec-23	Dec-24	Dec-23	Mar-24
1	SEGMENT REVENUE (Revenue from Operations)	3					
	- BRANDED	4,432.32	4,656.63	4,125.86	13,087.37	12,708.02	16,914.78
*4"	- BULK	5,297.23	1,963.07	5,622.88	10,251.31	14,596.53	18,861.83
	REVENUE FROM OPERATIONS	9,729.55	6,619.70	9,748.74	23,338.68	27,304.55	35,776.61
2	SEGMENT RESULTS (EBITDA)				10-10		
	- BRANDED	141.17	462.09	360.36	1,205.55	1,307.37	1,798.62
	- BULK	227.88	(26.02)	(411.65)	80.31	(700.57)	(927.01)
	TOTAL SEGMENT PROFIT BEFORE INTEREST, TAX, DEPRECIATION AND AMORTISATION	369.05	436.07	(51.29)	1285.86	606.80	871.61
3	SEGMENT RESULTS (EBIT)						
	- BRANDED	135.36	456.27	344.16	1,188.11	1,258.79	1,733.68
	- BULK	192.21	(64.20)	(441.42)	(26.72)	(789.87)	(1054.05)
	TOTAL SEGMENT PROFIT BEFORE INTEREST AND TAX	327.57	392.07	(97.26)	1161.39	468.92	679.63
	Less : Finance cost	116.09	93.99	95.16	310.84	327.24	428.67
	Less: Other Unallocable Expenditure net of unallocable Income	(49.01)	26.12	56.17	26.79	194.14	155.94
	PROFIT BEFORE TAX	260.49	271.96	(248.59)	823.76	(52.46)	95.02
4	SEGMENT ASSETS						
	- BRANDED	6,144.98	7,880.50	6,171.69	6,144.98	6,171.69	5,491.33
	- BULK	6,138.13	4,071.81	5,842.73	6,138.13	5,842.73	6,380.28
	UNALLOCABLE	5,338.96	3,500.00	4,506.11	5,338.96	4,506.11	5,022.30
	TOTAL ASSETS	17,622.07	15,452.31	16,520.53	17,622.07	16,520.53	16,893.91
5	SEGMENT LIABILITIES						
	- BRANDED	915.14	987.81	1,599.24	915.14	1,599.24	1,685.51
	- BULK	1,166.60	438.71	1,015.31	1,166.60	1,015.31	916.94
	- UNALLOCABLE	5,510.75	4,209.92	4,760.01	5,510.75	4,760.01	4,988.86
	TOTAL LIABILITIES di Natur	7,592.49	5,636.44	7,374.56	7,592.49	7,374.56	7,591.31

Portlodi

- B. Statement on deviation or variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc. **Not Applicable**
- C. Disclosure of outstanding default on loans and debt securities Not Applicable
- D. Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) **Not Applicable**
- E. Statement on impact of audit qualifications (for audit report with modified opinion) submitted alongwith Annual Audited Financial Results (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) **Not Applicable**